B. Mahé

发表

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience

P. Chevallier, P. Moreau, C. Touzeau, 2020, Bone Marrow Transplantation.

Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.

R. Bataille, S. Hermouet, B. Mahé, 1997, Hematology and cell therapy.

Early intensive therapy with autotransplantation for high-risk Hodgkin's disease.

P. Moreau, B. Dupas, B. Mahé, 1993, Leukemia & lymphoma.

Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial

P. Feugier, M. Béné, C. Ferrand, 2012, Bone Marrow Transplantation.

Long‐term outcome of monoclonal (type 1) cryoglobulinemia

B. Grosbois, O. Decaux, P. Jégo, 2014, American journal of hematology.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

P. Chevallier, M. Mohty, P. Moreau, 2011, Leukemia.

Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study.

P. Moreau, L. Planche, B. Mahé, 2008 .

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia

P. Feugier, S. Leprêtre, B. Grosbois, 2008, British journal of haematology.

Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity

P. Chevallier, M. Mohty, P. Moreau, 2012, Bone Marrow Transplantation.

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

O. Casasnovas, P. Feugier, S. Leprêtre, 2012, Blood.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?

P. Chevallier, M. Mohty, P. Moreau, 2012, Transplantation.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

P. Feugier, S. Leprêtre, R. Letestu, 2017, The Lancet. Haematology.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

P. Chevallier, P. Moreau, C. Leux, 2016, Annals of Hematology.

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

B. Pégourié, G. Mufti, D. Oscier, 1996, Blood.

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study

S. Leprêtre, A. Delmer, S. Choquet, 2017, Leukemia & lymphoma.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

R. Bouabdallah, M. Hallek, V. Leblond, 2014, Blood.

Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

P. Chevallier, M. Mohty, M. Béné, 2016, Seminars in hematology.

Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma

M. Mohty, P. Moreau, L. Planche, 2012, Leukemia & lymphoma.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

P. Feugier, S. Leprêtre, R. Letestu, 2023, Blood advances.

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

G. Salles, B. Pégourié, P. Feugier, 2020, Blood.

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

G. Salles, B. Pégourié, P. Feugier, 2019, The Lancet. Haematology.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

P. Feugier, S. Leprêtre, R. Letestu, 2018, Haematologica.

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

E. Kimby, C. Buske, J. Dreyhaupt, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

M. Dimopoulos, C. Buske, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom’s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

E. Kimby, M. Dimopoulos, C. Buske, 2020 .

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

M. Dimopoulos, C. Buske, S. Treon, 2018, The New England journal of medicine.

Acquired von Willebrand Syndrome Associated With Monoclonal Gammopathy: A Single-Center Study of 36 Patients

M. Trossaërt, B. Mahé, M. Hamidou, 2011, Medicine.

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

P. Chevallier, P. Moreau, C. Leux, 2020, Annals of Hematology.

CD38 expression and secondary 17p deletion are important  prognostic factors in chronic lymphocytic leukaemia

R. Bataille, P. Chevallier, P. Moreau, 2002, British journal of haematology.

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study

P. Moreau, A. Moreau, B. Dupas, 1998, Bone Marrow Transplantation.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

P. Chevallier, M. Mohty, M. Béné, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria

C. Bodet-Milin, S. Querellou, P. Salaun, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

M. Amiot, P. Moreau, C. Touzeau, 2017, Haematologica.

A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2020, Cancer medicine.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

H. Dombret, A. Stamatoullas, P. Greenberg, 2008, Blood.

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy

P. Moreau, N. Ifrah, P. Colombat, 2002, Bone Marrow Transplantation.

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2020 .

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

S. Leprêtre, S. Kremer, L. Fornecker, 2015, Haematologica.